31 OCTOBER 2026 | DAY 1

Vitiligo Expert Consensus Meeting

Evidence review • Expert discussion • Consensus voting | Focused evidence presentations with structured discussion and live refinement of consensus statements.

MORNING PROGRAMME • 09:00–11:00

Building the consensus: activity, biomarkers and topical care

TIME	SESSION / TOPIC	SCOPE / DISCUSSION FOCUS	LEAD / SPEAKER	DURATION
09:00–09:05	Introduction and consensus methodology	Objectives; evidence-presentation format; voting process; definition of consensus; handling of statements without consensus; rules for wording modification and re-voting.	Prof. Davinder Parsad	5 min
09:05–09:15	Welcome Message		Dr. Yan Valle and Prof. Torello Lotti	10 min
09:15–09:30	Opening discussion & alignment	Clarify meeting objectives, expected outputs, strength of recommendations and how evidence gaps/expert opinion will be labelled.	All experts / Chair	15 min
09:30–09:40	Genetics and Biomarkers	Genetic susceptibility; biomarkers of activity, progression, stability and treatment response; role in routine practice and precision treatment.	Dr. Sejal Jain	10 min
09:40–10:00	Discussion & consensus voting	Which biomarkers are ready for routine use? Can biomarkers alter treatment selection, predict progression or guide surgery? Identify “recommended”, “optional” and “research-only” domains.	Moderated expert panel	20 min
10:00–10:10	Disease Activity, Stability and Disease States	Defining active, progressive, stable and refractory vitiligo; clinical activity measures; medical versus surgical stability; relapse and recurrence.	Dr. Hitaishi Mehta	10 min
10:10–10:40	Discussion & consensus voting	Agree practical definitions of activity/stability, minimum duration of stability for medical vs surgical decisions, and terminology for relapse/recurrence/refractory disease.	Moderated expert panel	30 min
10:45–11:00	Tea / Coffee Break			15 min

31 OCTOBER 2026 | DAY 1 CONTINUED

Systemic therapy, JAK inhibitors and therapeutic sequencing

Late-morning programme • 11:00–14:00

TIME	SESSION / TOPIC	SCOPE / DISCUSSION FOCUS	LEAD / SPEAKER	DURATION
11:00–11:10	**Topical Therapy**	Topical corticosteroids, calcineurin inhibitors, topical JAK inhibitors and emerging agents; site-specific selection; duration, maintenance and combinations.	Dr. Surakshya Baral	**10 min**
11:10–11:30	**Discussion & consensus voting**	Preferred first-line topical therapy by site/age; treatment duration; intermittent strategies; maintenance; topical JAK positioning; practical combinations with light-based therapy.	Moderated expert panel	**30 min**
11:30–11:40	**Systemic Therapy and Disease Arrest**	Oral mini-pulse corticosteroids; conventional immunosuppressive/immunomodulatory therapy; antioxidants/adjuncts; indications, duration, monitoring and assessment of arrest.	Dr. Ishita Kaushal	**10 min**
11:40–12:00	**Discussion & consensus voting**	When is systemic therapy justified? Define disease arrest and expected time to arrest; preferred OMP strategy; role and hierarchy of conventional agents and adjuncts; monitoring and stopping rules.	Moderated expert panel	**20 min**
12:00–12:10	**JAK Inhibitors and Therapeutic Sequencing**	Systemic and topical JAK inhibitors; selection; JAK + OMP and JAK + phototherapy; duration; inadequate response; switching and sequencing.	Dr. Anubha Dev	**10 min**
12:10–13:00	**Discussion & consensus voting**	Position topical vs systemic JAK inhibition; patient selection and safety; sequencing with OMP/phototherapy; response thresholds; when to continue, combine, switch or stop.	Moderated expert panel	**40 min**
13:00–14:00	**Lunch Break**			**60 min**

31 OCTOBER 2026 | DAY 1 CONTINUED

Phototherapy, patient journey and special situations

Afternoon programme • 14:00–16:30 | Provisional consensus statements consolidated at day end.

TIME	SESSION / TOPIC	SCOPE / DISCUSSION FOCUS	LEAD / SPEAKER	DURATION
14:00–14:10	**Phototherapy and Device-Based Management**	NB-UVB; targeted phototherapy/excimer; dosing and duration; home phototherapy; combinations; difficult sites; stopping rules and maintenance.	Dr. Shubham Guleri	**10 min**
14:10–14:30	**Discussion & consensus voting**	Standardize initiation, escalation, duration and stopping rules; define role of home NB-UVB and targeted devices; combinations and maintenance; difficult-site expectations.	Moderated expert panel	**20 min**
14:30–15:00	**Mapping Vitiligo: From Patient Journey to National Data**	Charting Vitiligo: launch of patient-centred tools and national initiatives.	Dr. Yan Valle	**30 min**
TIME TBC	**Discussion & consensus voting**			**TBC**
15:00–15:15	**Tea / Coffee Break**			**15 min**
15:15–15:25	**Special Groups and Special Situations**	Children, pregnancy/lactation, older adults; segmental vitiligo; rapidly progressive/extensive disease; acral/mucosal disease, leukotrichia; autoimmune comorbidity and challenging scenarios.	Dr. Madhav Verma	**10 min**
15:25–15:55	**Discussion & consensus voting**	Develop scenario-based recommendations for children/pregnancy, segmental disease, rapid progression, extensive disease, acral/mucosal disease and leukotrichia; identify areas where evidence is insufficient.	Moderated expert panel	**30 min**
15:55–16:30	**Day 1 synthesis: provisional consensus statements**	Read back provisional statements from each domain; flag wording issues, overlaps and statements lacking consensus; assign items for focused reconsideration on Day 2.	Prof. Davinder Parsad + session leads	**35 min**

1 NOVEMBER 2026 | DAY 2

From outcomes to clinical pathways and final consensus

Half-day programme • 09:00–13:00 | Practical consultation framework, consensus voting and dissemination.

TIME	SESSION / TOPIC	SCOPE / DISCUSSION FOCUS	LEAD / SPEAKER	DURATION
09:00–09:10	**Outcome Measures and Patient-Reported Outcomes, Clinical Trials**	VASI and clinician-reported measures; standardized photography; repigmentation and colour match; stabilization; PROs, QoL, treatment burden, satisfaction and core outcome sets.	Dr. Sejal Jain	**10 min**
09:10–09:45	**Discussion & consensus voting**	Which outcomes should be minimum standard in practice and studies? Define clinically meaningful repigmentation/stabilization; photography standards; role and frequency of PRO/QoL assessment.	Moderated expert panel	**35 min**
09:45–09:55	**Surgical Management**	Candidate selection; stability required; grafting/cellular techniques; site-specific approaches; adjunctive phototherapy; predictors of response and management of failure.	Dr. Roshini N	**10 min**
10:00–10:20	**Discussion & consensus voting**	Agree stability prerequisites, technique selection by site/extent, timing of adjunctive therapy, management of leukotrichia and surgical failure, and minimum outcome documentation.	Moderated expert panel	**20 min**
10:20–10:45	**Patient Support Group**	“Nothing about us without us”: patients as partners in vitiligo care.	Dr. Maya Tulpule	**15 min**
10:45–11:00	**Discussion**	How can patients contribute to research, and how can patient support groups be integrated?		**15 min**
11:00–11:30	**Integrated treatment algorithm discussion**	Build a practical pathway from activity assessment to disease arrest, repigmentation, maintenance and surgery. Address sequencing across topical therapy, systemic therapy, phototherapy, JAK inhibitors and surgery; this pathway will feed directly into the structured first-consultation workshop.	Prof. Davinder Parsad + all experts	**30 min**
11:30–12:00	**Consensus Workshop: Building the 10–15-Minute Structured First Vitiligo Consultation**	Each panelist brings 5–10 essential first-visit questions/items. Live build of a consensus minimum dataset and timed consultation flow: 0–2 min—patient agenda/expectations; 2–5 min—onset, progression/activity, previous treatment and adherence; 5–8 min—focused examination, extent/activity, difficult sites/leukotrichia and standardized photographs; 8–10 min—relevant comorbidity/family history and psychosocial/QoL screen; 10–13 min—diagnosis/prognosis, treatment goals and shared decision-making; 13–15 min—prescription, safety advice and follow-up plan. Output: one-page patient pre-consult questionnaire + clinician checklist + 10–15-minute consultation template.	Moderated discussion	**30 min**
12:00–12:30	**Statements without consensus: discussion and re-voting**	Revisit all contentious statements from Day 1 and Day 2; review evidence and minority views; clarify wording; split compound statements where necessary; conduct second-round voting.	Dr. Hitaishi Mehta / Dr. Anubha Dev	**30 min**
12:30–13:00	**Consensus manuscript and dissemination plan**	Agree writing groups, statement tables, grading/strength language, authorship responsibilities, timelines, target journal, and plan for algorithm/figures	All experts / Chair	**30 min**